Ask AI
ProCE Banner Activity

PALM 007: Safety of Tecovirimat for the Treatment of Mpox in the Democratic Republic of Congo

Conference Coverage
Slideset

In the PALM 007 study in the Democratic Republic of Congo, tecovirimat for the treatment of clade I Mpox was found to present no safety concerns, after reported lack of efficacy.

Released: July 21, 2025

Expiration: January 20, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner